Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label meningococcal B and ACWY vaccination study in healthy adult laboratory workers
2008-007182-23Phase 2Completed
- Sponsor
- Health Protection Agency
- Start
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of meningococcal group B multicomponent recombinant vaccine and Meningococcal conjugate vaccine quadrivalent in meningococcal disease, sponsored by Health Protection Agency. Primary endpoints: Proportion attaining protective serum bactericidal antibody titres against MenB target strains and Proportion attaining protective serum bactericidal antibody titres against MenA, C, Y and W135 strains. Started Mar 2010; status: completed.
02
Drugs
meningococcal group B multicomponent recombinant vaccineMeningococcal conjugate vaccine quadrivalent
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2008-007182-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007182-23.